Crossmark

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment

Crossref DOI link: https://doi.org/10.1016/j.reumae.2022.06.001

Published Print: 2023-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aomar-Millán, Ismael Francisco

Salvatierra, Juan

Callejas-Rubio, José Luis

Raya-Álvarez, Enrique
License Information

Text and Data Mining valid from 2023-02-01
More Information

This article is maintained by: Elsevier

Article Title: Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2022.06.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2022.01.003

Content Type: simple-article

Copyright: © 2022 Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below